Advertisement
Canada markets close in 5 hours 23 minutes

  • S&P/TSX

    21,889.85
    +95.95 (+0.44%)
     

  • S&P 500

    5,487.01
    +9.11 (+0.17%)
     

  • DOW

    39,227.88
    +100.08 (+0.26%)
     

  • CAD/USD

    0.7307
    +0.0007 (+0.10%)
     

  • CRUDE OIL

    81.65
    +0.75 (+0.93%)
     

  • Bitcoin CAD

    84,899.80
    +399.97 (+0.47%)
     

  • CMC Crypto 200

    1,294.80
    +28.66 (+2.26%)
     

  • GOLD FUTURES

    2,335.40
    +22.20 (+0.96%)
     

  • RUSSELL 2000

    2,025.54
    +7.42 (+0.37%)
     

  • 10-Yr Bond

    4.2810
    -0.0350 (-0.81%)
     

  • NASDAQ

    17,856.56
    +51.41 (+0.29%)
     

  • VOLATILITY

    12.40
    -0.15 (-1.19%)
     

  • FTSE

    8,212.70
    -12.63 (-0.15%)
     

  • NIKKEI 225

    39,341.54
    -325.53 (-0.82%)
     

  • CAD/EUR

    0.6818
    -0.0013 (-0.19%)
     
MARKETS LIVE BLOG:

STOCKS CLIMB BUT MICRON SLIDES, WITH DATA IN FOCUS

U.S. economic growth for last quarter revised up slightly to 1.4% annual rate

Ionis to present at TD Cowen Genetic Medicines & RNA Summit

PR Newswire
·1 min read

CARLSBAD, Calif., June 17, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in a fireside chat at the virtual TD Cowen Genetic Medicines & RNA Summit on Thursday, June 20, 2024.

Ionis logo (PRNewsfoto/Ionis Pharmaceuticals, Inc.)
Ionis logo (PRNewsfoto/Ionis Pharmaceuticals, Inc.)

A live webcast of this presentation can be accessed on the Investors & Media section of the Ionis website at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available on the Ionis website within 48 hours and will be archived for a limited time.

About Ionis Pharmaceuticals
For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients.

ADVERTISEMENT

To learn more about Ionis, visit Ionis.com and follow us on X (Twitter) and LinkedIn.

Ionis Pharmaceuticals Investor Contact:
D. Wade Walke, Ph.D. – ir@ionis.com – 760-603-2331

Ionis Pharmaceuticals Media Contact:
Hayley Soffer – media@ionis.com – 760-603-4679

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/ionis-to-present-at-td-cowen-genetic-medicines--rna-summit-302174669.html

SOURCE Ionis Pharmaceuticals, Inc.